TNF-R1 Antibody: ATTO 594

TNF-R1 Antibody: ATTO 594

• Background: The Tumor Necrosis Factor Receptor (TNFR) also known as Cluster of differentiation (CD120) is a protein that belongs to the (TNF)/ (TNFR) superfamily. TNF interacts with two distinct receptors TNFR1 and TNFR2. These receptors share no homology on their cytoplasmic sequences(1,3).TNFR1 also known as p55/p60 is a high affinity receptor for TNF-α. The TNFR1 has an extracellular domain with variable numbers of cysteine-rich repeats. The functional properties of TNFR1 are targets in new therapies for osteoporosis, chronic inflammatory and autoimmune diseases (1, 2). The TNF-α/TNFR1 receptor complex is responsible for the recruitment and the subsequent activation of the caspase (aspartate-specific cysteine proteases) that regulate apoptosis.
• Description: Rabbit Anti-Mouse TNF-R1 Polyclonal
• Specifications: Detects ~55kDa. Other bands present may be the result of oligomerization, self-aggregation and/or cleavage of the TNF-R1 extracellular domain.
• Product Name Alternative: Cancer, Apoptosis, Cell Signaling, Cardiovascular System, Atherosclerosis
• CAS Number: 9007-83-4
• UNSPSC: 12352203
• Gene ID: 7132
• Swiss Prot: P19438
• Cellular Locus: Cell Membrane | Golgi Apparatus | Golgi Apparatus Membrane
• Host: Rabbit
• Species Reactivity: Human, Mouse, Rat, Bovine, Monkey, Dog, Rabbit
• Immunogen: Peptide corresponding to AA 20-43 of the mouse TNF-R1 sequence, identical to rat and human over those residues
• Target: TNFR1
• Clonality: Polyclonal
• Conjugation: ATTO 594
• Validated Applications: IHC, ICC/IF
• Purification: Peptide Affinity Purified
• Concentration: 1 mg/ml
• Dilution: WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
• Weight: 0.1
• Buffer: 640.91mM DMSO, 136.36mM Ethanolamine, and 9.09mM Sodium Bicarbonate in 90.9% PBS
• Precautions: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
• References & Citations: 1. Kontermann R.E., et al. (2008) J Immunother. 31(3):225-34. 2. Hehlgans T. and Pfeffer K. (2005) Immunology. 115(1):1-20. 3. Al-Lamki S., et al. (2005) The Faseb Journal. 19:1638-1645.